FDA approval for Novartis' melanoma combo

1st May 2018 Uncategorised 0

Tafinlar/Mekinist combo is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation

More: FDA approval for Novartis' melanoma combo
Source: News